Zoetis Canada recently announced that Draxxin® (tulathromycin) Injectable Solution has been approved by Health Canada for the treatment of foot rot in sheep.
Zoetis Canada Press Release:
DRAXXIN® (TULATHROMYCIN) INJECTABLE SOLUTION IS APPROVED IN CANADA FOR THE TREATMENT OF OVINE FOOT ROT ASSOCIATED WITH DICHELOBACTER NODOSUS
Montreal – September 7, 2018. Zoetis Canada announces that Draxxin® (tulathromycin) Injectable Solution has received approval from Health Canada for the treatment of ovine foot rot associated with Dichelobacter nodosus when systematic treatment is required due to the presence of active lesions. Foot rot, which is caused when the bacteria Dichelobacter nodosus infects the horn of the sheep’s hoof,1 is highly contagious and has serious implications, such as lameness and reduced production.
DRAXXIN®
Draxxin® Injectable Solution is a ready-to-use sterile parenteral preparation containing tulathromycin, a semisynthetic macrolide antibiotic. Each mL of Draxxin® Injectable Solution contains 100 mg of tulathromycin. Draxxin® has a long track record of safety and efficacy across species: in cattle, as an antibiotic approved for the treatment of bovine respiratory disease (BRD), infectious bovine keratoconjunctivitis (IBK) and foot rot; in swine, as an antibiotic for the treatment of swine respiratory disease (SRD); and now in sheep for the treatment of foot rot. Draxxin® is available in Canada in five formats (20mL, 50mL, 100 mL, 250 mL, 500 mL) to meet the needs of all operations.
AN EXPANDING PORTFOLIO OF PRODUCTS TO SUPPORT OVINE HEALTH
With its broad portfolio of products—which include the recent additions of the Glanvac® 6 vaccine and StartectTM parasiticide—Zoetis is committed to the health of Canada’s sheep flocks.
ABOUT ZOETIS
Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on 60 years of experience, we deliver quality medicines and vaccines, complemented by diagnostic product and genetics tests and supported by a range of services.
For more information, please contact:
Dr. Melodie Chan I Senior Manager Veterinary Services, Zoetis I 403-550-2139
France Lanthier I Product Manager – Cattle, Zoetis I 514-459-3841
Reference:
1. Baird, A. N. and Pugh, D. G. (2012) Chapter 11 - Diseases of the Musculoskeletal System, p.321-323. In Sheep and goat medicine. 2nd ed. Maryland Heights, Mo : Saunders.
Zoetis®, Draxxin® and Glanvac® 6 are registered trademarks and StartectTM is a trademark of Zoetis or its licensors, used under license by Zoetis Canada Inc.
© 2018 Zoetis Canada. All rights reserved.